Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PulseSelect vs FARAPULSE pulsed field ablation: Comparative analysis of myocardial, neural-injury and hemolysis biomarkers and short-term outcomes.

International journal of cardiology. Heart & vasculature·2026
Same author

Computational modeling identifies protective mechanisms of estrogen and testosterone against atrial fibrosis.

American journal of physiology. Heart and circulatory physiology·2026
Same author

Bile Acids Rewiring Cardiometabolic Systems.

The Canadian journal of cardiology·2026
Same author

Immunology of Cardiometabolic Health and Disease: From Novelty to Necessity.

The Canadian journal of cardiology·2026
Same author

Antiplatelet Therapy and All-Cause Mortality After Transcatheter Aortic Valve Replacement: The TRITAVI Registry.

JACC. Advances·2026
Same author

Potentially futile outcome after uncomplicated TAVI: Insights from the TRITAVI registry.

American heart journal·2026

Related Experiment Video

Updated: May 1, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

12.7K

Cardiac safety assays.

Jordi Heijman1, Niels Voigt1, Leif G Carlsson2

  • 1Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.

Current Opinion in Pharmacology
|April 12, 2014
PubMed
Summary
This summary is machine-generated.

Assessing drug-induced cardiac arrhythmia risk, like torsades de pointes (TdP), is crucial. This review covers methods for evaluating drug proarrhythmia liability and discusses novel cardiac safety assays for drug approval.

More Related Videos

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
10:30

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Published on: August 4, 2022

3.0K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.0K

Related Experiment Videos

Last Updated: May 1, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

12.7K
Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
10:30

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Published on: August 4, 2022

3.0K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.0K

Area of Science:

  • Pharmacology and Toxicology
  • Cardiovascular Research
  • Drug Safety Evaluation

Background:

  • Cardiac safety is paramount in drug development, with drug-induced torsades de pointes (TdP) arrhythmia posing a significant risk.
  • Regulatory agencies require thorough assessment of TdP risk before drug approval and prescription.

Purpose of the Study:

  • To review current methodologies for assessing drug proarrhythmia liability.
  • To discuss the inherent challenges in evaluating drug-induced cardiac safety.
  • To highlight emerging and promising novel cardiac safety assays.

Main Methods:

  • Review of existing scientific literature and regulatory guidelines.
  • Analysis of surrogate markers for TdP risk, including QT-interval prolongation.
  • Examination of assays targeting the human ether-a-go-go-related gene (hERG) potassium channel (IKr).

Main Results:

  • Established methodologies for assessing cardiac safety are essential but face challenges.
  • Inhibition of the hERG channel is a key indicator of TdP risk.
  • Novel assays show promise for more accurate and comprehensive cardiac safety evaluations.

Conclusions:

  • Comprehensive cardiac safety assessment, including hERG channel interaction, is vital for drug approval.
  • Overcoming challenges in current methodologies is necessary for reliable proarrhythmia risk prediction.
  • Advancements in cardiac safety assays are crucial for ensuring patient safety and efficient drug development.